BR112015030457A2 - Método para regular positivamente a expressão de antígeno - Google Patents

Método para regular positivamente a expressão de antígeno

Info

Publication number
BR112015030457A2
BR112015030457A2 BR112015030457A BR112015030457A BR112015030457A2 BR 112015030457 A2 BR112015030457 A2 BR 112015030457A2 BR 112015030457 A BR112015030457 A BR 112015030457A BR 112015030457 A BR112015030457 A BR 112015030457A BR 112015030457 A2 BR112015030457 A2 BR 112015030457A2
Authority
BR
Brazil
Prior art keywords
antigens
antigen expression
expression
positively regulate
regulate antigen
Prior art date
Application number
BR112015030457A
Other languages
English (en)
Inventor
H Larsen Roy
Repetto-Llamazares Ada
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of BR112015030457A2 publication Critical patent/BR112015030457A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODO PARA REGULAR POSITIVAMENTE A EXPRESSÃO DE ANTÍGENO. A presente invenção refere-se à radioimunoconjugados que são capazes de regular positivamente a expressão de um ou mais antígenos. Os antígenos regulados positivam ente podem ser os antígenos que são alvos dos radioimunoconjugados ou antígenos diferentes expressos nas mesmas células. A presente invenção também se refere a métodos de tratamento de câncer e de doenças e distúrbios do sistema imunológico, utilizando esta expressão aumentada de antígenos.
BR112015030457A 2013-06-07 2014-06-06 Método para regular positivamente a expressão de antígeno BR112015030457A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201370313 2013-06-07
PCT/EP2014/061824 WO2014195460A1 (en) 2013-06-07 2014-06-06 Method for upregulating antigen expression

Publications (1)

Publication Number Publication Date
BR112015030457A2 true BR112015030457A2 (pt) 2017-08-22

Family

ID=50896309

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030457A BR112015030457A2 (pt) 2013-06-07 2014-06-06 Método para regular positivamente a expressão de antígeno

Country Status (19)

Country Link
US (2) US20160101199A1 (pt)
EP (2) EP3332813B1 (pt)
JP (2) JP6335284B2 (pt)
KR (1) KR102033819B1 (pt)
CN (2) CN105451781B (pt)
AU (1) AU2014276827B2 (pt)
BR (1) BR112015030457A2 (pt)
CA (1) CA2911962A1 (pt)
DK (2) DK3003402T3 (pt)
ES (2) ES2741643T3 (pt)
HK (2) HK1217438A1 (pt)
IL (1) IL242892A (pt)
MX (1) MX367346B (pt)
NO (1) NO3003402T3 (pt)
PH (1) PH12015502713A1 (pt)
RU (1) RU2681953C2 (pt)
SG (1) SG11201510035UA (pt)
UA (1) UA119443C2 (pt)
WO (1) WO2014195460A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
UA122405C2 (uk) * 2015-02-26 2020-11-10 Сайєнконс Ас Радіофармацевтичні розчини з переважними властивостями
US20170000900A1 (en) * 2015-06-08 2017-01-05 Immunogen, Inc. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
MA42706A (fr) 2015-08-28 2021-04-14 Debiopharm Int Sa Anticorps et dosages pour la détection de cd37
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
EP3661557A4 (en) * 2017-07-31 2021-04-14 Actinium Pharmaceuticals, Inc. TREATMENTS FOR HEMATOLOGICAL MALIGNOMAS
EP3706785A4 (en) * 2017-11-10 2021-08-04 Actinium Pharmaceuticals, Inc. COMBINATION THERAPY FOR TREATMENT OF A HEMATOLOGICAL DISEASE
EP3713607A1 (en) * 2017-11-22 2020-09-30 Nordic Nanovector ASA Radioimmunoconjugates in combination with other drugs as treatment against nhl
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY136203A (en) * 1998-08-11 2008-08-29 Idec Pharma Corp Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US20040018557A1 (en) * 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
SI1912675T1 (sl) * 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
RU2658438C2 (ru) * 2011-12-13 2018-06-21 Нордик Нановектор Аса Химерное терапевтическое антитело нн1 против cd-37
US20130309224A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with rituximab

Also Published As

Publication number Publication date
JP2018150323A (ja) 2018-09-27
SG11201510035UA (en) 2016-01-28
US20190008989A1 (en) 2019-01-10
CN105451781B (zh) 2018-07-27
CA2911962A1 (en) 2014-12-11
NO3003402T3 (pt) 2018-06-16
MX2015016832A (es) 2016-05-31
HK1217438A1 (zh) 2017-01-13
CN105451781A (zh) 2016-03-30
ES2662964T3 (es) 2018-04-10
US10646599B2 (en) 2020-05-12
EP3003402B1 (en) 2018-01-17
MX367346B (es) 2019-08-15
EP3332813A1 (en) 2018-06-13
WO2014195460A1 (en) 2014-12-11
PH12015502713B1 (en) 2016-03-14
KR20160039178A (ko) 2016-04-08
JP2016520640A (ja) 2016-07-14
CN108939065A (zh) 2018-12-07
AU2014276827B2 (en) 2018-11-15
KR102033819B1 (ko) 2019-10-17
PH12015502713A1 (en) 2016-03-14
AU2014276827A1 (en) 2016-01-28
IL242892A (en) 2017-07-31
UA119443C2 (uk) 2019-06-25
JP6335284B2 (ja) 2018-05-30
DK3332813T3 (da) 2019-06-24
EP3003402A1 (en) 2016-04-13
DK3003402T3 (en) 2018-04-16
HK1256497B (zh) 2020-06-05
RU2015154447A (ru) 2017-07-17
US20160101199A1 (en) 2016-04-14
RU2681953C2 (ru) 2019-03-14
RU2015154447A3 (pt) 2018-03-07
ES2741643T3 (es) 2020-02-11
EP3332813B1 (en) 2019-05-29
JP6590985B2 (ja) 2019-10-16

Similar Documents

Publication Publication Date Title
BR112015030457A2 (pt) Método para regular positivamente a expressão de antígeno
BR112018003984A2 (pt) anticorpos
BR112019005305A2 (pt) compostos espirocíclicos
BR112018005164A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
BR112017016902A2 (pt) composição farmacêutica, respectivo uso e método para tratar câncer
BR112018008783A2 (pt) terapia-alvo de câncer
BR112016015399A2 (pt) método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
CR20170011A (es) Compuestos de heteroarilo para la inhibición de cinasa
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016026264A2 (pt) sistema e método dos mesmos para otimizar o tempo de inicialização de computadores com múltiplas cpus.
BR112018074232A2 (pt) compostos inibidores de egfr
BR112018002427A2 (pt) terapias de combinação para tratamento do câncer
BR112016018980A2 (pt) método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica
BR112017002433A2 (pt) anticorpos anticeramida
EA201792058A1 (ru) Виротерапия комбинацией антител
BR112017021194A2 (pt) compostos espirocíclicos
BR112016006210A2 (pt) terapia e vacina contra gripe
DK3463436T3 (da) Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2623 DE 13/04/2021.